155
Participants
Start Date
December 31, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
MORAb-009
Monoclonal antibody administered once weekly by intravenous injection.
Placebo
As per package insert.
Gemcitabine
Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
AZ Sint Maarten - digestive oncology unit - campus, Mechelen
Services de gastro-entérologie et d'oncologie, CHC Saint-Joseph, Liège
Centre Hospitalier Jolimont-Lobbes, Haine-Saint-Paul
Hospital de la Santa Creu i Sant Pau, Barcelona
South Carolina Oncology Associates, PA, Columbia
Arena Oncology Associates, P.C., Lake Success
University of Pittsburgh Medical Center, Pittsburgh
Hospital Madrid, Madrid
Hospital Clinico Universitario San Carlos, Madrid
Hospital 12 de Octubre, Madrid
Hanover Medical Specialists, MD, Wilmington
Baptist Cancer Institute - Jacksonville, Jacksonville
Palm Beach Institute of Hematology and Oncology, Boynton Beach
Hematology Oncology Associates of the Palm Beaches, Lake Worth
Gabrail Cancer Center, Canton
Providence Cancer Center, Oncology, Clinical Trials, Southfield
Medical College of Wisconsin Clinical Cancer Center, Milwaukee
Hematology-Oncology Associates of Illinois, LLC, Skokie
Carle Clinic Assoc., Urbana
University of Kansas Medical Center, Westwood
Jayne Gurtler, MD, Laura Brinz, MD, & Angelo Russo, MD, Metairie
University of Oklahoma Health Sciences Center, Oklahoma City
Arlington Cancer Center, Arlington
Baylor College of Medicine, Houston
South Texas Onocology Hemotology, PA, San Antonio
Southern California Permanente Medical Group, San Diego
Sharp Memorial Hospital, San Diego
Kaiser Permanente, Vallejo
Providence Western Washington Oncology, Lacey
Moores UCSD Cancer Center, La Jolla
Cancer Center of Central Connecticut, Southington
Connecticut Oncology & Hematology, Torrington
The Center for Cancer and Hematologic Disease, Cherry Hill
Queen Elizabeth II Health Sciences Center, Halifax
London Regional Cancer Program London Health Sciences Centre, London
Princess Margaret Hospital, Toronto
Jewish General Hospital - Montreal, Montreal
Klinik fuer Tumorbiologie an der Albert-Ludwigs-Universität Freiburg, Freiburg im Breisgau
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Heidelberg
SLK-Kliniken Heilbronn GmbH, Medizinische Klinik III, Heilbronn
Universitätsklinikum Ulm, Innere Medizin I, Ulm
II. Medizinische Klinik des Klinikums rechts der Isar, München
Stadtische Kliniken Bielefeld-Mitte, Klinik fur Hamatologie und Onkologie, Bielefeld
Charité, Universitätsmedizin Berlin, Berlin
Hospital Clinic i Provincial de Barcelona, Barcelona
Lead Sponsor
Morphotek
INDUSTRY